Premium
P3‐031: THE CRITICAL PATH FOR ALZHEIMER'S DISEASE: HIPPOCAMPAL VOLUME AS AN ENRICHMENT BIOMARKER IN TRIALS OF PATIENTS WITH MILD COGNITIVE IMPAIRMENT
Author(s) -
Conrado Daniela J.,
Nicholas Timothy,
Burton Jackson,
Arnerić Stephen P.,
Chen Danny,
Stone Julie A.,
Sinha Vikram,
Willis Brian A.,
Kern Volker D.,
Hill Derek L.,
Novak Gerald P.,
Gold Lisa H.,
Cole Patricia E.,
Matthews Dawn C.,
Xie Zhiyong,
Wang Wenping,
Hendrix James,
Wolz Robin,
Gordon Mark Forrest,
Romero Klaus
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.1386
Subject(s) - alzheimer's disease neuroimaging initiative , clinical dementia rating , biomarker , neuroimaging , clinical trial , oncology , alzheimer's disease , dementia , medicine , psychology , sample size determination , disease , neuroscience , statistics , biochemistry , chemistry , mathematics
forced-choice and open-ended questions investigating whether participants shared their results with others, used the information to instruct lifestyle changes, would repeat amyloid imaging, and would enroll in another AD trial. Data from forced-choice responses are reported here. Results: We interviewed 33 of 43 (77%) individuals eligible for this study. All participants shared their amyloid imaging results with two or more people. Participants most commonly shared results with spouses (88%), adult children (85%) and friends (85%). Fifty-eight percent of participants shared their result with their primary care physician. Most participants indicated that, had their result been different, they would have made changes to their diet (76%), exercise routine (73%), prescription medications (67%), and vitamins/supplements (73%). Half of participants had long-term care insurance (49%), and most had an advance directive (97%). Seven participants lacking long-term care insurance indicated they would have made a change had their result been different. The participant without an advance directive indicated she would have established one had her result been different. Of participants with advance directives, 22% would have made changes had the scan result been different. When asked the probability of undergoing another amyloid scan, if given the opportunity, 91% of participants indicated that they would be very (64%) or somewhat (27%) likely to do so. When asked the probability of participating in another AD prevention trial, 100% of participants indicated that they would be very (64%) or somewhat (36%) likely to do so. Conclusions: Disclosure of elevated amyloid may spur some individuals to adopt risk-reducing lifestyle strategies; not elevated results may not. Despite receiving personal biomarker results that indicated reduced relative risk for AD, interest in future biomarker testing remained high in this sample.